The most fragmented care market in Europe: mapping Germany's consolidation runway

A market-structure briefing for investors, operators, and lenders — built on Nonnela Data's coverage of 18,560 active German care facilities, 3,788 operators, and roughly 550,000 beds. Where the consolidation runway is, where pricing power isn't, and how Germany compares to the rest of Europe.

---

Most write-ups of the German care market start with the demographic tailwind and stop there. Everyone already knows Europe is aging. The more useful question for anyone deploying capital is structural: who owns the supply, how concentrated is it, and where does that structure create — or destroy — returns?

We hold data on 18,560 active care facilities in Germany, run by 3,788 distinct operators, spanning roughly 550,000 beds. That dataset tells a clear story, and it is not the one the demographic headline implies.

The headline: the most fragmented major care market in Europe

Here is the single number that should frame every German care thesis. Across our data, the largest single operator in Germany runs about 0.7% of facilities. The top four operators combined — the standard CR4 concentration measure — control just 2.2%.

To put that in context, here is how Germany's operator concentration compares to the other large markets we cover:

Market	Facilities	Distinct operators	CR4 (top-4 share of facilities)
Germany	18,560	3,788	2.2%
France	8,586	4,006	4.0%
United Kingdom	12,959	6,628	5.1%
Netherlands	3,264	406	6.8%
Spain	1,246	239	4.3%
Austria	1,539	418	18.5%
Sweden	256	46	11.7%
Norway	508	144	17.5%

Germany is an outlier at the bottom. A market of ~550,000 beds where no operator has managed to assemble even a single-digit percentage share is, structurally, the opposite of France (where EMEIS/ORPEA and a handful of groups are consolidated and visible) or the UK (where private-equity roll-ups have been running for two decades). Neighbouring Austria is already 8× more concentrated than Germany on this measure.

For a consolidator, fragmentation is the opportunity: it means acquisition targets are plentiful, individually small, rarely auctioned competitively, and priced by owners without the leverage a scaled platform enjoys. For an incumbent operator, the same number says the land grab hasn't happened yet. The German roll-up is, in structural terms, still on the starting line.

Why it's this fragmented: the nonprofit backbone

The fragmentation isn't random — it's baked into who runs German care. Our operator data is dominated not by listed chains but by the country's welfare associations (Freie Wohlfahrtspflege): AWO, Caritas, Diakonie, the German Red Cross (DRK), ASB, and Volkssolidarität. These are federated, regionally autonomous nonprofits — Caritas alone appears in our data through dozens of independent diocesan and regional entities rather than one corporate parent.

That structure has two consequences for capital:

1. A large share of supply is effectively off-market. Church and welfare beds don't trade like assets. The genuinely acquirable universe is the for-profit tail — names like Alloheim, Kursana, and Korian — which sits below the nonprofits in scale and, notably, at lower median day rates in our data (~€80–86/day vs €99–113 for the welfare operators). "Private chain" does not mean "premium price" in Germany.
2. Consolidation has to be assembled, not bought. There is no dominant platform to acquire as a shortcut to scale. A buyer builds share one regional cluster at a time — which rewards operational discipline and local density over financial engineering.

Pricing power: the number that should temper the thesis

Fragmentation is the bull case. Pricing is the check on it.

The median listed private-pay rate in Germany is about €94/day in our data — roughly €2,800/month at the low care tier — with the middle of the market clustered tightly between the high-€80s and mid-€110s. That is a narrow band for a market this large, and it reflects a hard structural fact: German care pricing is heavily negotiated with the Pflegekassen (statutory long-term-care insurers) at the state level, not set freely by operators.

The practical implication for underwriting: top-line pricing power is limited and politically constrained. The resident's personal share (Eigenanteil) has climbed to a national average of €3,245/month in the first year (vdek, January 2026), but that increase is driven by rising costs — staff, capital, the training levy — passing through to residents, not by operators expanding margin. Returns in German care are earned on the cost and occupancy side — labour productivity, real-estate efficiency, and regional density — not on price. Any model that assumes rate-driven upside is mispricing the market.

Where the beds are — and the capital-intensity signal

Germany's ~550,000 beds sit across facilities with a median size of roughly 68–75 beds. That is small and operationally sub-scale by international standards, and it points directly at the value-creation lever: there is a long tail of sub-scale, often older assets where consolidation, modernisation, and back-office centralisation are the return drivers.

Two data caveats we hold ourselves to:

• We have verified bed counts for a subset of facilities; the official Pflegestatistik remains the authority on total national capacity, and our ~550,000 figure reflects our verified coverage, not a census.
• Regional supply/demand modelling in our platform is complete for some markets (e.g. Austria) but only partial for Germany, so we are deliberately not publishing a national bed-gap number here. When the reporting is thin, we say so rather than extrapolate.

The quality regime lenders and buyers need to understand

One diligence trap worth flagging: Germany abolished its nursing-home star ratings (Pflegenoten) in 2019. Any target still marketing an old 1.0–1.3 grade is quoting a defunct number. The replacement is an indicator-based system measuring real care outcomes (pressure ulcers, weight loss, mobility preservation, restraint use). In our data, across 3,319 German homes with these indicators, the average "no deficit" score is about 80%.

For a buyer or lender, this matters twice: the old grades are worthless for diligence, and the new indicators are comparable across a portfolio — which makes them a genuine underwriting input rather than marketing. A portfolio's indicator spread is a cleaner signal of operational quality (and regulatory/reputational risk) than anything the old regime produced.

What the data says for each side of the table

For investors / capital allocators. Germany is the clearest fragmentation play in European senior housing: deep supply, no dominant owner, an acquirable for-profit tail, and a structural aging tailwind. The catch is that the thesis has to be a cost-and-density roll-up, not a pricing story — model margin from scale and occupancy, not rate.

For operators. The land grab hasn't happened. Regional density is unclaimed in most of the country, and the sub-scale asset base means well-run local clusters can out-operate the nonprofit incumbents on cost without needing pricing power. First movers to build regional scale set the terms.

For lenders. Pricing is insurer-anchored and stable, which supports predictable cash flows — but the collateral base skews small and old, and quality risk now lives in indicator data, not a headline grade. Underwrite the building's capital-cost recovery (Investitionskosten) and the operator's indicator spread, and treat any advertised Pflegenote as a red flag for stale management.

Methodology

Figures reflect Nonnela Data's coverage of the German market as of July 2026: 18,560 active facilities, 3,788 distinct operators, and roughly 550,000 verified beds. Concentration measures (top-operator share, CR4) are computed on facility counts across our active, operator-attributed records and are directional measures of market structure, not official market-share statistics. Median day rates cover the ~6,100 German facilities carrying at least one listed private-pay rate and are advertised tariffs, not realised revenue. Cross-country concentration figures are computed on the same basis per market and are not currency- or definition-normalised, so they are used here only for structural comparison, not price comparison. The €3,245 first-year Eigenanteil (vdek, January 2026) and the 2019 abolition of the Pflegenoten are external figures and should be checked against current-year sources for a specific transaction. This briefing is market research, not investment advice.